graphic
abstract
highlight
itz
antifung
anticanc
agent
broadspectrum
enteroviru
inhibitor
osbp
identifi
novel
target
itz
itz
bind
osbp
inhibit
osbpmedi
lipid
exchang
membran
contact
site
itz
also
inhibit
hepat
c
viru
replic
summari
itraconazol
itz
wellknown
antifung
agent
also
anticanc
activ
studi
identifi
itz
broadspectrum
inhibitor
enterovirus
eg
polioviru
coxsackieviru
rhinoviru
demonstr
itz
inhibit
viral
rna
replic
target
oxysterolbind
protein
osbp
osbprel
protein
consist
specif
antagonist
also
inhibit
enteroviru
replic
knockdown
osbp
inhibit
viru
replic
wherea
overexpress
osbp
counteract
antivir
effect
itz
itz
bind
osbp
inhibit
function
ie
shuttl
cholesterol
membran
therebi
like
perturb
virusinduc
membran
alter
essenti
viral
replic
organel
format
itz
also
inhibit
hepat
c
viru
replic
also
reli
osbp
togeth
data
implic
molecular
target
itz
point
essenti
role
lipid
exchang
viru
replic
target
antivir
drug
et
al
repurpos
itraconazol
treatment
advanc
prostat
cancer
noncompar
random
phase
ii
trial
men
metastat
castrationresist
prostat
cancer
oncologist
arita
kinas
iii
beta
oxysterolbind
protein
accumul
unesterifi
cholesterol
poliovirusinduc
membran
structur
microbiol
immunol
itraconazol
act
novel
target
oxysterolbind
protein
osbp
protein
essenti
role
lipid
transfer
famili
picornavirida
contain
mani
import
human
anim
pathogen
genu
enteroviru
includ
polioviru
pv
coxsackieviru
cv
echoviru
sever
number
enterovirus
eg
human
rhinoviru
hrv
except
pv
vaccin
avail
prevent
infect
enterovirus
antivir
drug
avail
treatment
import
human
picornavirus
includ
hepat
viru
human
parechoviru
hpev
wellknown
anim
pathogen
footandmouth
diseas
viru
encephalomyocard
viru
emcv
genom
enterovirus
consist
kb
singlestrand
rna
molecul
posit
polar
rna
encod
singl
polyprotein
proteolyt
process
viral
proteas
structur
protein
nonstructur
protein
viral
genom
replic
assembl
viral
host
protein
locat
intracellular
membran
term
replic
organel
ro
ro
form
result
virusinduc
remodel
secretori
pathway
membran
like
start
golgi
complex
hsu
et
al
eventu
result
complex
network
tubulovesicular
membran
belov
et
al
limpen
et
al
viral
modif
lipid
homeostasi
thought
play
major
role
ro
format
viral
protein
play
major
role
membran
rearrang
recruit
essenti
host
factor
enteroviru
replic
ro
iii
beta
golgiloc
lipid
kinas
gener
phosphat
arita
hsu
et
al
function
import
elev
level
ro
remain
establish
viral
rnadepend
rnapolymeras
pol
bind
vitro
unknown
whether
import
recruit
andor
activ
infect
cell
hsu
et
al
altern
lipid
may
particip
ro
format
facilit
recruit
host
protein
membranemodifi
properti
cholesterol
critic
membran
compon
determin
membran
fluiditi
regul
format
function
membranebound
complex
lipid
protein
sever
rna
virus
hepat
c
viru
hcv
dengu
west
nile
viru
remodel
cellular
cholesterol
landscap
make
intracellular
hostcel
membran
conduc
effici
genom
replic
rothwel
et
al
wang
et
al
enterovirusinduc
rearrang
secretori
pathway
membran
tubulovesicular
ro
structur
may
also
depend
alter
cholesterol
homeostasi
recent
data
suggest
enterovirus
stimul
clathrinmedi
endocytosi
transport
cholesterol
plasma
membran
extracellular
medium
ro
ilnytska
et
al
howev
intracellular
cholesterol
traffick
pathway
may
also
subvert
enterovirus
creat
ro
recent
oxysterolbind
protein
osbp
shown
play
key
role
transport
cholesterol
endoplasm
reticulum
er
golgi
osbp
link
er
transgolgi
membran
socal
ergolgi
membran
contact
site
mcss
shuttl
sterol
golgi
back
er
hydrolyz
exchang
cycl
drive
deliveri
sterol
transgolgi
selfregul
local
osbp
golgi
osbp
osbprel
protein
orp
constitut
famili
relat
protein
base
gene
structur
sequenc
subdivid
six
subfamili
osbp
closest
rel
also
call
belong
subfamili
orp
lipidbind
domain
initi
thought
specif
sterol
howev
recent
structur
analysi
suggest
orp
abil
bind
second
lipid
either
sterol
nonsterol
ligand
mani
orp
includ
osbp
ffatmotif
recogn
erresid
vap
receptor
ntermin
pleckstrin
homolog
ph
domain
bind
link
varieti
organel
although
function
orp
well
understood
becom
clear
orp
execut
divers
function
lipid
sens
lipid
transport
cell
signal
raychaudhuri
prinz
weberboyvat
et
al
set
identifi
novel
inhibitor
enteroviru
replic
screen
nih
clinic
collect
ncc
librari
us
food
drug
administr
fda
approv
drug
histori
use
clinic
trial
treatment
wide
varieti
diseas
similar
collect
fdaapprov
drug
proven
rich
sourc
undiscov
bioactiv
therapeut
potenti
identifi
itraconazol
itz
broadspectrum
inhibitor
enteroviru
replic
itz
wellknown
antifung
drug
inhibit
cytochrom
requir
sterol
biosynthesi
lestner
hope
addit
itz
exert
anticanc
activ
inhibit
angiogenesisthrough
disturb
mtor
signal
vascular
endotheli
growth
factor
receptor
traffickingand
hedgehog
hh
signal
pathway
kim
et
al
nacev
et
al
xu
et
al
itz
found
efficaci
patient
sever
cancer
type
multipl
phase
clinic
studi
antonaraki
et
al
kim
et
al
rudin
et
al
demonstr
known
target
itz
explain
antivir
activ
itz
instead
evid
present
osbp
novel
target
itz
direct
bind
itz
osbp
local
ro
disrupt
lipidshuttl
function
account
antivir
effect
itz
perform
screen
ncc
identifi
novel
inhibitor
replic
like
enterovirus
kill
host
cell
therebi
caus
cytopath
effect
cpe
screen
ncc
microscop
observ
compound
prevent
develop
cpe
multicycl
replic
assay
identifi
itz
figur
one
hit
determin
spectrum
antivir
activ
test
itz
repres
panel
picornavirus
multicycl
cpereduct
assay
itz
exhibit
antivir
effect
enterovirus
examin
belong
sever
speci
effect
concentr
ec
valu
mm
mm
tabl
addit
emcv
cardioviru
genu
member
inhibit
itz
contrast
equin
rhiniti
viru
erav
aphthoviru
genu
member
parechoviru
genu
member
insensit
itz
exclud
possibl
antivir
activ
due
toxic
side
effect
determin
effect
itz
viru
product
singl
replic
cycl
similar
multicycl
cpereduct
assay
itz
activ
emcv
erav
singl
replic
cycl
figur
without
appar
toxic
figur
itz
also
inhibit
saffold
viru
safv
replic
human
cardioviru
figur
thu
itz
exert
broad
antivir
activ
enterovirus
cardiovirus
itz
inhibit
viral
rna
genom
replic
next
determin
effect
itz
translat
replic
transfect
emcv
rna
name
subgenom
replicon
part
capsidcod
region
replac
firefli
luciferas
gene
genom
rna
emcv
renilla
luciferas
gene
insert
upstream
code
region
posit
control
use
guanidinehcl
dipyridamol
wellknown
potent
inhibitor
emcv
replic
respect
two
hour
transfect
rna
rna
replic
taken
place
yet
van
kuppeveld
et
al
luciferas
level
unaffect
indic
itz
inhibit
viral
genom
translat
figur
howev
later
time
point
luciferas
product
replicon
decreas
demonstr
itz
affect
legend
continu
next
page
cell
report
februari
author
rna
replic
importantli
itz
affect
viral
polyprotein
synthesi
process
figur
target
itz
itz
wide
use
antifung
drug
inhibit
fungal
enzym
itz
also
shown
inhibitori
activ
toward
human
relat
cytochrom
addit
itz
azol
famili
antifung
drug
includ
posaconazol
ketoconazol
fluconazol
voriconazol
figur
also
inhibit
slightli
lower
similar
potenc
itz
warrilow
et
al
zhang
et
al
test
whether
drug
exert
antivir
activ
use
recombin
virus
rlucemcv
carri
renilla
luciferas
gene
upstream
code
region
mm
posaconazol
inhibit
replic
rlucemcv
remain
azol
display
antivir
activ
concentr
mm
similar
result
obtain
multicycl
cpereduct
assay
shown
result
rule
possibl
inhibit
underli
antivir
activ
itz
structur
relat
analog
posaconazol
itz
also
inhibit
hedgehog
hh
signal
pathway
like
interf
function
g
proteincoupl
receptorlik
protein
smoothen
kim
et
al
test
sever
smoothen
antagonist
viral
luciferas
assay
smoothen
antagonist
kaadcyclopamin
chen
et
al
taipal
et
al
effect
replic
rlucemcv
figur
indic
antivir
activ
itz
mediat
inhibit
hh
pathway
antiangiogen
activ
itz
attribut
least
part
inhibit
mtor
signal
pathway
disrupt
shuttl
cholesterol
plasma
membran
late
endosomeslysosom
therebi
induc
accumul
cholesterol
endolysosom
system
xu
et
al
found
cholesterol
stain
filipin
redistribut
itz
posaconazol
also
ketoconazol
inhibit
viru
replic
two
human
cell
line
figur
hela
cell
figur
moreov
mtor
inhibitor
rapamycin
effect
picornaviru
replic
beretta
et
al
wong
et
al
togeth
result
suggest
inhibit
viru
replic
itz
posaconazol
due
disrupt
endosom
cholesterol
shuttl
cholesterolrel
mtor
inhibit
addit
aforement
molecular
pathway
target
itz
itz
report
disturb
nglycosyl
nacev
et
al
howev
nglycosyl
inhibitor
tunicamycin
affect
polioviru
doeden
et
al
replic
data
shown
itz
also
shown
antagon
estrogen
receptor
era
cheng
et
al
era
agonist
bestradiol
affect
figur
emcv
replic
figur
final
itz
report
target
pglycoprotein
udpglucuronosyltransferas
erb
none
like
mediat
antivir
activ
itz
potent
inhibit
ketoconazol
cheng
et
al
walski
et
al
wang
et
al
affect
viru
replic
mutat
confer
resist
inhibitor
also
confer
resist
itz
itz
inhibit
activ
first
step
identifi
antivir
target
itz
studi
effect
replic
mutant
virus
previous
select
resist
inhibitor
carri
mutat
confer
resist
inhibitor
eg
enviroxim
van
der
schaar
et
al
prove
less
sensit
itz
wildtyp
wt
singlecycl
replic
assay
figur
multicycl
cpereduct
assay
figur
mutat
shown
protect
inhibitor
ie
van
der
schaar
et
al
also
provid
crossresist
itz
figur
similarli
mutat
pv
also
shown
protect
inhibitor
arita
et
al
protect
pv
itz
figur
result
impli
link
lipid
mechan
antivir
action
itz
determin
whether
itz
inhibit
activ
transient
transfect
cell
genet
encod
sensor
ie
gfptag
ph
domain
local
sensor
specif
depend
activ
control
cell
overlap
golgiloc
figur
upon
treatment
inhibitor
redistribut
cytosol
itz
howev
decreas
local
fact
itz
caus
small
increas
amount
golgiloc
appar
cell
line
stabli
express
sensor
show
homogen
moder
express
level
figur
also
upon
stain
specif
antibodi
inhibitor
van
der
schaar
et
al
decreas
level
wherea
itz
increas
level
figur
replic
complet
block
itz
see
eg
figur
thu
permit
monitor
lipid
treat
cell
untreat
itztreat
cell
infect
visual
use
antibodi
level
visual
use
antibodi
clearli
increas
compar
uninfect
cell
figur
indic
itz
also
inhibit
activ
infect
cell
rule
target
itz
next
turn
signal
step
downstream
ie
protein
bind
lipid
assess
whether
known
protein
could
target
itz
perform
target
identif
small
interf
rna
sirna
sensit
tiss
assay
arita
et
al
tiss
encompass
sirna
knockdown
candid
target
protein
potenti
biolog
effect
low
concentr
compound
among
number
golgiloc
protein
knockdown
osbp
ph
domaincontain
protein
enhanc
inhibitori
effect
low
concentr
mm
itz
pv
replic
figur
impli
osbp
possibl
antivir
target
itz
assess
possibl
sever
experi
first
osbp
antagonist
burgett
et
al
potent
inhibit
replic
figur
confirm
pharmacolog
target
osbp
inhibit
enteroviru
replic
itz
mutat
provid
resist
figur
akin
itz
inhibit
enterovirus
test
well
emcv
erav
data
shown
importantli
affect
endolysosom
cholesterol
distribut
figur
support
previou
conclus
effect
unlik
explain
antivir
effect
itz
second
similar
pv
wang
et
al
sirna
knockdown
osbp
inhibit
replic
figur
replic
also
inhibit
osbp
knockdown
differ
statist
signific
line
lower
sensit
itz
figur
third
overexpress
osbp
restor
replic
presenc
itz
figur
confirm
inhibit
viral
replic
itz
mediat
osbp
overexpress
fail
rescu
replic
osbp
overexpress
provid
rescu
inhibitor
data
shown
indic
specif
experiment
setup
besid
osbp
also
target
burgett
et
al
knockdown
none
orp
also
sensit
pv
itz
figur
overexpress
counteract
inhibitori
effect
replic
figur
also
attempt
test
effect
deplet
although
tiss
assay
knockdown
potenti
effect
itz
abl
achiev
robust
knockdown
mrna
level
therefor
conclud
unambigu
whether
import
viru
replic
problem
knockdown
also
observ
other
like
due
essenti
role
cell
prolifer
surviv
charman
et
al
collect
result
indic
osbp
novel
target
itz
involv
mechan
antivir
action
replic
hcv
also
requir
osbp
inhibit
wang
et
al
line
find
enterovirus
found
itz
posaconazol
select
azol
inhibit
hcv
replic
cell
cultur
figur
ec
valu
inhibit
hcv
replic
itz
compar
obtain
enterovirus
tabl
togeth
data
clearli
demonstr
itz
inhibit
osbp
function
virus
differ
famili
depend
osbp
function
inhibit
itz
importantli
rna
virus
sensit
inhibit
osbp
dengu
viru
replic
recent
observ
insensit
wang
et
al
also
show
replic
mous
hepat
viru
coronaviru
insensit
itz
data
shown
establish
osbp
possibl
novel
target
itz
want
studi
itz
target
protein
avail
tool
focus
osbp
remaind
studi
line
publish
data
burgett
et
al
caus
massiv
recruit
overexpress
gfposbp
golgi
apparatu
mark
stain
endogen
figur
similar
reloc
observ
endogen
osbp
figur
itz
posaconazol
azol
lack
antivir
activ
redistribut
osbp
manner
similar
livecel
imag
perform
studi
dynam
gfposbp
reloc
compound
addit
compound
gfposbp
primarili
local
cytosol
golgi
pattern
faintli
visibl
minut
addit
compound
c
cell
treat
hr
nm
mm
itz
fix
stain
filipin
hela
cell
transfect
construct
encod
osbp
egfp
neg
control
hr
infect
moi
moi
treat
mm
mm
itz
nm
dmso
renilla
luciferas
level
determin
hr
pi
viru
titer
hr
pi
determin
endpoint
titrat
e
hela
cell
transfect
sirna
osbp
posit
control
scrambl
sirna
day
infect
moi
viru
titer
hr
pi
determin
endpoint
titrat
knockdown
effici
determin
quantit
pcr
immunofluoresc
figur
mt
assay
use
test
effect
cell
viabil
f
cell
transfect
sirna
target
orp
famili
member
roman
number
indic
orp
subfamili
infect
treat
itz
analyz
g
hela
cell
transfect
construct
encod
osbp
enhanc
gfp
infect
treat
nm
data
analyz
c
hela
cell
transfect
gfposbp
treat
dmso
mm
itz
nm
reloc
osbp
imag
livecel
confoc
laser
scan
microscopi
cell
imag
overnight
first
min
imag
taken
fast
possibl
min
interv
interv
stepwis
increas
min
hr
onward
repres
group
cell
shown
imag
frame
movi
quantif
rel
gfposbp
signal
golgi
apparatu
five
cell
condit
c
error
bar
indic
sem
scale
bar
correspond
mm
see
also
movi
gfposbp
fluoresc
golgi
clearli
increas
cell
treat
either
itz
continu
increas
expens
cytoplasm
signal
figur
movi
previous
report
disrupt
structur
golgi
apparatu
burgett
et
al
also
observ
min
onward
gfpposit
puncta
becam
numer
time
figur
itztreat
cell
golgi
pattern
becam
affect
hour
later
appear
less
dispers
treat
cell
investig
whether
itz
block
lipid
transfer
activ
osbp
use
set
vitro
liposom
assay
supplement
experiment
procedur
measur
transport
dehydroergosterol
dhe
figur
figur
erlik
golgilik
liposom
itz
inhibit
steroltransf
activ
purifi
osbp
dosedepend
manner
inhibitori
concentr
ic
nm
figur
mm
itz
posaconazol
select
azol
strongli
inhibit
dhe
transfer
transport
liposom
assay
although
less
potent
known
osbp
ligand
figur
also
observ
dosedepend
inhibit
transfer
itz
ic
mm
figur
posaconazol
slightli
inhibit
wherea
azol
show
activ
figur
unknown
reason
stimulatori
effect
transfer
observ
depend
cholesterol
content
erlik
liposom
ic
valu
suggest
itz
potent
toward
sterol
transfer
importantli
technic
reason
sterol
assay
perform
differ
condit
therefor
directli
compar
investig
would
need
establish
whether
itz
inde
potent
inhibit
sterol
shuttl
itz
may
inhibit
lipid
transfer
function
osbp
directli
inhibit
function
ord
transfer
lipid
indirectli
disrupt
bind
osbp
liposom
investig
whether
itz
inhibit
bind
osbp
liposom
studi
whether
interfer
interact
ffatmotif
vapa
erlik
liposom
phdomain
golgilik
liposom
end
perform
liposom
floatup
experi
use
recombin
fragment
osbp
contain
ph
domain
ffat
motif
amino
acid
phffat
figur
presenc
vapa
phffat
bound
erlik
liposom
interact
disrupt
mm
itz
figur
interact
phffat
golgilik
liposom
disrupt
mm
itz
either
figur
likewis
vapa
interact
phffat
recruit
golgilik
liposom
also
insensit
mm
itz
figur
togeth
liposom
floatup
assay
show
itz
interfer
bind
osbp
liposom
via
vapa
establish
whether
itz
inhibit
lipid
transfer
activ
ord
made
use
previous
establish
assay
limit
tryptic
proteolysi
osbp
cleav
osbp
three
major
fragment
kda
fragment
contain
phdomain
ffatmotif
two
fragment
kda
kda
deriv
ord
previous
shown
ordderiv
fragment
retain
lipid
transfer
activ
also
absenc
inact
kda
fragment
found
itz
still
inhibit
dhe
figur
figur
transfer
osbp
subject
tryptic
proteolysi
figur
result
suggest
itz
inhibit
steroland
activ
osbp
target
ord
inhibitori
effect
itz
osbp
function
minim
vitro
system
impli
itz
directli
inhibit
osbp
biochem
defin
bind
detail
measur
bind
itz
gfposbp
use
microscal
thermophoresi
mst
molecul
complex
distribut
differ
temperatur
field
depend
size
charg
hydrat
shell
bind
itz
osbp
affect
hydrat
shell
therebi
thermophoret
behavior
itz
alter
thermophoret
profil
purifi
gfposbp
figur
dosedepend
manner
indic
direct
bind
normal
fit
data
three
independ
measur
demonstr
itz
bind
osbp
k
nm
figur
monophas
shape
bind
curv
indic
like
singl
bind
site
itz
osbp
although
data
rule
two
site
nearli
ident
k
test
whether
osbp
play
role
format
andor
mainten
ro
examin
local
infect
cell
uninfect
cell
osbp
mainli
distribut
throughout
cytosol
osbp
local
golgi
apparatu
figur
coloc
transgolgi
network
marker
data
shown
infect
cell
osbp
local
markedli
chang
ie
golgi
pattern
lost
osbp
appear
dispers
structur
throughout
interact
itz
gfptag
osbp
investig
use
mst
data
three
separ
measur
normal
plot
sigmoid
doserespons
curv
fit
shown
mean
valu
sem
statist
signific
drugtreat
condit
calcul
compar
drug
control
see
also
figur
cytoplasm
coloc
viral
protein
marker
ro
mander
coeffici
overlap
osbp
figur
examin
whether
osbp
local
ro
manner
cell
infect
replic
allow
progress
uninhibit
hr
inhibitor
ad
min
cell
process
microscopi
inhibit
decreas
coloc
osbp
mander
coeffici
wherea
treatment
itz
increas
coloc
osbp
romark
mander
coeffici
figur
enhanc
recruit
osbp
ro
upon
itz
treatment
reminisc
hr
pi
cell
treat
min
dmso
vehicl
control
mm
bf
inhibitor
mm
itz
hr
pi
cell
fix
process
immunofluoresc
antibodi
osbp
viral
protein
imag
use
confoc
laser
scan
microscopi
b
mander
coeffici
overlap
osbp
calcul
dmso
cell
bf
cell
itz
cell
shown
mean
sem
asterisk
indic
statist
signific
compar
dmsotreat
control
scale
bar
correspond
mm
enhanc
golgiloc
osbp
upon
treatment
itz
osbp
inhibitor
may
therefor
caus
inhibit
remov
ro
test
directli
whether
itz
inhibit
shuttl
function
osbp
ro
cell
infect
replic
allow
progress
uninhibit
hr
itz
ad
hr
cell
process
microscopi
intens
ro
quantifi
itz
treatment
caus
strong
increas
signal
ro
increas
wherea
treatment
reduc
figur
line
effect
drug
osbp
recruit
figur
effect
observ
upon
treatment
guanidin
inhibitor
viral
protein
includ
rule
observ
effect
mere
due
inhibit
replic
thu
result
demonstr
infect
cell
itz
prevent
remov
ro
compar
observ
uninfect
cell
figur
test
whether
itz
also
inhibit
cholesterol
shuttl
ro
cell
infect
treat
similar
describ
cholesterol
visual
filipin
stain
coloc
filipin
quantifi
use
pearson
correl
coeffici
dmsotreat
cell
filipin
partial
overlap
pearson
itz
significantli
reduc
coloc
filipin
pearson
indic
itz
inhibit
redistribut
cholesterol
ro
figur
similarli
reduc
local
osbp
ro
figur
also
inhibit
cholesterol
shuttl
ro
pearson
wherea
guanidin
decreas
overlap
filipin
thu
demonstr
osbp
recruit
ro
action
itz
inhibit
cholesteroltransf
function
osbp
infect
cell
enterovirus
alter
cellular
lipid
homeostasi
remodel
hostcel
membran
replic
organel
usurp
number
host
protein
arita
et
al
hsu
et
al
howev
yet
littl
known
underli
mechan
ident
host
factor
involv
elucid
mechan
action
inhibitor
viru
replic
proven
instrument
obtain
novel
insight
mechan
viral
replic
studi
identifi
itz
wide
use
antifung
drug
current
also
explor
anticanc
agent
novel
broadspectrum
inhibitor
enterovirus
cardiovirus
hcv
show
none
wellestablish
target
itz
ie
mtor
hh
explain
antivir
activ
instead
identifi
protein
osbp
novel
target
itz
antivir
effect
mediat
osbp
master
regul
lipid
homeostasi
mcss
er
transgolgi
apparatu
exchang
cholesterol
membran
propos
control
mc
stabil
osbp
prototyp
member
famili
orp
group
protein
whose
cellular
function
remain
poorli
understood
identifi
osbp
target
itz
pharmacolog
inhibit
sirna
knockdown
rescu
replic
overexpress
demonstr
import
protein
viru
replic
furthermor
osbp
local
ro
manner
itz
directli
bound
purifi
osbp
inhibit
cholesterol
activ
osbp
vitro
liposom
assay
also
live
uninfect
cell
itz
inhibit
transport
function
osbp
ie
transport
cholesterol
er
golgi
transport
golgi
er
lead
increas
level
golgi
therebi
caus
accumul
osbp
likewis
infect
cell
itz
increas
level
ro
lead
enhanc
recruit
osbp
inhibit
accumul
cholesterol
ro
thu
demonstr
itz
inhibit
lipidshuttl
function
osbp
vitro
also
infect
uninfect
cell
enterovir
protein
play
critic
role
ro
format
recruit
lead
accumul
lipid
ro
arita
arita
et
al
hsu
et
al
show
osbp
subsequ
recruit
ro
via
data
indic
erro
mcss
osbp
exchang
cholesterol
either
newli
synthes
er
origin
lipid
droplet
storag
pool
mobil
er
lead
accumul
cholesterol
ro
arita
find
agreement
recent
paper
suggest
osbp
shuttl
cholesterol
hrv
ro
base
inhibitori
effect
hrv
replic
osbp
knockdown
treatment
roulin
et
al
find
level
cholesterol
elev
expens
cholesterylest
ie
form
cholesterol
store
lipid
droplet
enterovirusinfect
cell
ilnytska
et
al
roulin
et
al
suggest
store
cholesterol
mobil
transport
ro
addit
uptak
cholesterol
endocytosi
suggest
contribut
accumul
cholesterol
ro
ilnytska
et
al
role
cholesterol
accumul
ro
far
establish
cholesterol
profound
import
membran
properti
membran
fluiditi
format
lipid
microdomain
therebi
like
import
membran
rearrang
deform
underli
ro
format
addit
cholesterol
alter
suggest
affect
viral
polyprotein
process
effici
ilnytska
et
al
activ
osbp
also
import
homeostasi
lipid
ergolgi
mcss
act
concert
pi
transfer
protein
suppli
pi
synthesi
golgi
membran
cert
transfer
ceramid
golgi
sphingomyelin
synthesi
therebi
gener
diacylglycerol
dag
peretti
et
al
importantli
osbp
ligand
eg
chang
local
cert
modifi
sphingomyelin
synthesi
burgett
et
al
perri
ridgway
inhibitor
osbpmedi
lipid
shuttl
itz
may
thu
affect
accumul
cholesterol
also
perturb
homeostasi
lipid
sphingomyelin
dag
whether
contribut
inhibit
ro
format
andor
function
remain
establish
studi
work
arita
et
al
implic
role
addit
osbp
enteroviru
replic
unfortun
littl
known
biolog
function
role
propos
organ
cytoskelet
vimentin
network
cell
prolifer
surviv
sterol
transfer
charman
et
al
wang
et
al
howev
unlik
osbp
local
golgi
normal
condit
respons
ligand
charman
et
al
wang
et
al
therefor
seem
unlik
transport
cholesterol
er
golgi
similar
manner
osbp
overexpress
counteract
inhibitori
effect
itz
viru
replic
thu
remain
establish
possibl
heteromultim
wyle
et
al
import
viru
replic
requir
investig
besid
osbp
orp
appear
target
itz
though
may
still
import
viru
replic
itz
shown
inhibit
angiogenesi
via
mtor
growth
hhdepend
cancer
cell
exact
molecular
mechan
antitumor
activ
itz
await
elucid
remain
establish
whether
osbp
inhibit
contribut
anticanc
activ
itz
via
pathway
osbp
overexpress
show
counter
antivir
activ
itz
fail
prevent
inhibitori
effect
itz
mtor
hh
signal
shown
observ
suggest
itz
inhibit
antitumor
pathway
osbp
exclud
overexpress
approach
neutral
antivir
effect
itz
therefor
work
need
establish
whether
itz
exert
antitumor
activ
via
osbp
andor
sever
natur
product
recent
report
inhibit
growth
cultur
human
cancer
cell
line
osbp
therefor
collect
term
orpphilin
burgett
et
al
data
itz
target
osbp
justifi
classifi
itz
novel
orpphilin
plausibl
itz
inhibit
cancer
cell
growth
surviv
manner
independ
addit
mtor
hh
recent
two
inhibitor
pv
replic
shown
target
osbp
arita
et
al
although
bind
osbp
yet
shown
may
therefor
also
classifi
orpphilin
conclus
identifi
itz
broadspectrum
inhibitor
enteroviru
cardioviru
hcv
replic
exert
antivir
activ
novel
target
osbp
presum
inhibit
lipidshuttl
function
osbp
togeth
studi
provid
insight
enteroviru
replic
present
itz
orpphilin
potenti
novel
inhibitor
treat
enteroviru
infect
detail
publish
standard
method
cell
cultur
plasmid
viru
infect
replicon
transfect
tiss
assay
rescu
experi
analysi
viral
polyprotein
process
sirna
experi
immunofluoresc
microscopi
liposom
assay
provid
supplement
experiment
procedur
follow
compound
purchas
itraconazol
santa
cruz
biotechnolog
posaconazol
merck
ketoconazol
enzo
life
scienc
fluconazol
voriconazol
pfizer
pharmek
dipyridamol
guanidin
hydrochlorid
guhcl
bestradiol
sigma
aldrich
tocri
bioscienc
cyclopaminekaad
calbiochem
kind
gift
dr
k
shokat
univers
california
berkeley
macleod
et
al
provid
galapago
nv
isol
natur
burgett
et
al
bestradiol
dissolv
accord
manufactur
instruct
guhcl
dissolv
water
compound
dmso
nih
clinic
collect
purchas
nih
highli
druglik
compound
screen
inhibitor
use
reduct
cpe
readout
subconflu
monolay
buffalo
green
monkey
kidney
bgm
cell
plate
infect
ccid
per
well
compound
ad
final
concentr
mm
level
cpe
visual
assess
day
incub
c
full
cpe
develop
infect
untreat
control
well
livecel
imag
experi
hela
cell
transfect
pegfphosbp
treat
itz
solvent
control
dmso
imag
use
nikon
confoc
laser
scan
microscop
imag
process
quantifi
use
nikon
nisel
softwar
addit
detail
see
supplement
experiment
procedur
interact
itz
recombin
gfphosbpsii
human
osbp
ntermin
gfp
ctermin
streptagii
investig
mst
use
nanotemp
monolith
instrument
ntanalysi
softwar
nanotemp
technolog
data
present
mean
sem
replic
data
analyz
pairwis
comparison
condit
use
onetail
student
test
statist
signific
indic
p
p
p
jeroen
rpm
strate
lonnek
van
der
linden
lucian
albulescu
bigay
minetaro
arita
leen
delang
pieter
leyssen
hild
van
der
schaar
kjerstin
hw
lank
hendrik
jan
thibaut
rachel
ulfert
guillaum
drin
nina
schlinck
richard
w
wubbolt
navdar
sever
sarah
head
jun
liu
philip
beachi
maria
de
mattei
matthew
shair
vesa
olkkonen
johan
neyt
frank
jm
buffalo
green
monkey
bgm
kidney
cell
hela
cell
rhabdomyosarcoma
rd
cell
grown
co
dmem
readi
mix
paa
contain
fetal
bovin
serum
dmem
lonza
supplement
fetal
bovin
serum
vero
hela
h
bgm
cell
use
multicycl
antivir
assay
grown
mem
supplement
fc
integro
mm
lglutamin
mm
hepe
cell
carett
et
al
provid
thijn
brummelkamp
nki
amsterdam
netherland
grown
imdm
supplement
fetal
bovin
serum
primari
antibodi
use
rabbit
polyclon
antibodi
upstat
mous
monoclon
antibodi
echelon
bioscienc
rabbit
polyclon
wessel
et
al
mous
monoclon
dorobantu
et
al
affinitypurifi
rabbit
polyclon
antihuman
osbp
gene
id
secondari
antibodi
alexa
fluor
goatantirabbit
igg
alexa
fluor
goatantimous
igm
molecular
probe
plasmid
mammalian
express
provid
balla
nichd
nation
institut
health
bethesda
maryland
usa
rabbit
osbp
suchanek
et
al
previous
describ
produc
plasmid
pegfphosbp
mammalian
express
human
osbp
ntermin
egfptag
human
osbp
cdna
amplifi
pcr
insert
bamhi
site
clontechtakara
bio
produc
plasmid
mammalian
express
human
ntermin
hisand
xpresstag
human
cdna
amplifi
pcr
insert
xbai
site
c
invitrogen
plasmid
mammalian
express
human
osbp
ntermin
egfptag
ctermin
streptagii
affin
purif
gfphosbpsii
produc
amplifi
osbp
standard
pcr
use
revers
primer
encod
human
codonoptim
streptagii
clone
sali
bamhi
site
contain
renilla
luciferas
gene
upstream
capsid
code
region
mutant
virus
obtain
transfect
bgm
cell
rna
transcript
deriv
full
length
infecti
clone
wt
linear
sali
describ
de
palma
et
al
lank
et
al
wessel
et
al
emcv
strain
mengoviru
produc
rna
transcript
infecti
clone
gener
gift
palmenberg
linear
bamhi
luciferaseexpress
rlucemcv
deriv
infecti
clone
linear
bamhi
pv
pseudovirus
tepvfluc
mc
ie
firefli
luciferaseencod
pv
replicon
encapsid
capsid
protein
deriv
mahoney
prepar
report
previous
arita
et
al
saffold
viru
describ
previous
zoll
et
al
strain
brcr
gregori
strain
coe
obtain
nation
institut
public
health
environ
rivm
netherland
polioviru
sabin
strain
obtain
late
b
rombaut
vrije
universiteit
brussel
brussel
belgium
human
rhinovirus
kind
gift
joachim
seipelt
medic
univers
vienna
austria
erav
kindli
provid
david
rowland
tobi
tuthil
univers
leed
unit
kingdom
viru
titer
determin
endpoint
titrat
accord
method
reed
muench
express
cell
cultur
infect
dose
ccid
subconflu
monolay
indic
cell
line
seed
plate
treat
serial
dilut
itz
infect
viru
lowest
moi
result
full
cpe
within
day
medium
contain
fetal
bovin
serum
subsequ
cell
incub
three
day
complet
cpe
observ
infect
untreat
viru
control
cell
viabil
determin
mt
assay
incub
cell
aqueou
one
solut
cell
prolifer
assay
promega
measur
optic
densiti
well
nm
use
micropl
reader
raw
optic
densiti
valu
convert
percentag
untreat
uninfect
cell
control
subtract
background
valu
obtain
viru
control
concentr
compound
inhibit
virusinduc
cell
death
effect
concentr
ec
calcul
nonlinear
regress
analysi
cytotox
itz
assess
similar
setup
cytotox
concentr
cc
valu
deriv
cell
viabil
valu
determin
mt
assay
experi
perform
least
triplic
subconflu
monolay
cell
seed
plate
infect
viru
indic
moi
min
incub
viru
remov
fresh
compoundcontain
medium
ad
cell
incub
indic
length
time
measur
infecti
viru
particl
viru
releas
cell
three
round
freezethaw
viru
titer
determin
endpoint
dilut
assay
case
infect
rlucemcv
cell
lyse
pi
renilla
luciferas
activ
measur
renilla
luciferas
assay
system
promega
accord
manufactur
instruct
indic
cell
viabil
mt
assay
perform
parallel
describ
subgenom
replicon
assay
pv
perform
describ
previous
use
replicon
ppvfluc
mc
wt
respect
aminev
et
al
arita
et
al
van
ooij
et
al
subgenom
replicon
area
partial
emcv
complet
pv
replac
sequenc
encod
firefli
luciferas
linear
plasmid
replicon
construct
emcv
infecti
clone
vitro
transcrib
use
rna
polymeras
rna
transfect
cell
use
either
deaedextran
lipofectamin
rnaimax
firefli
pv
renilla
emcv
luciferas
activ
analyz
use
luciferas
assay
system
pv
renilla
luciferas
assay
system
emcv
promega
indic
time
point
hepat
c
viru
antivir
assay
perform
use
previous
describ
cell
contain
subgenom
hcv
replicon
huh
lohmann
et
al
cell
cultur
dmem
gibco
supplement
heatinactiv
fc
integro
netherland
nonessenti
amino
acid
iuml
penicillin
gibco
streptomycin
gibco
mgml
geneticin
gibco
antivir
assay
perform
describ
delang
et
al
briefli
cell
seed
densiti
x
cell
per
well
cell
cultur
plate
complet
dmem
follow
incub
hour
serial
dilut
test
compound
complet
dmem
ad
total
volum
replicon
rna
level
day
incub
determin
revers
transcript
quantit
polymeras
chain
reaction
rtqpcr
primer
use
detect
hcv
replicon
rna
forward
primer
revers
primer
probe
vivo
metabol
label
perform
describ
previous
briefli
bgm
cell
grown
plate
infect
moi
hr
incub
cell
starv
methionin
cystein
min
use
medium
devoid
amino
acid
protein
label
min
use
smethionin
presenc
absenc
compound
hr
pi
cell
lyse
protein
lysat
resolv
sdspage
polyacrylamid
gel
fix
analyz
autoradiographi
tiss
assay
perform
previous
describ
arita
et
al
short
cell
plate
transfect
sirna
pool
use
lipofectamin
rnaimax
transfect
reagent
invitrogen
hr
post
transfect
cell
infect
infecti
unit
pv
pseudoviru
treat
dmso
itz
firefli
luciferas
activ
measur
hr
pi
use
steadyglo
luciferas
assay
system
promega
effect
sirna
treatment
sensit
compound
determin
calcul
normal
pv
pseudoviru
infect
number
repres
level
firefli
luciferas
activ
compoundtr
sirnatransfect
cell
divid
firefli
luciferas
activ
measur
sirnatransfect
cell
absenc
compound
hela
cell
seed
plate
transfect
next
day
plasmid
encod
fulllength
human
rabbit
osbp
pegfphosbp
express
cell
infect
viru
titer
renilla
luciferas
valu
determin
describ
viru
infect
dt
sigma
h
cell
infect
viru
describ
viru
infect
mtsassay
essenti
describ
multicycl
cpereduct
assay
perform
evalu
effect
knockdown
cell
viabil
rna
isol
use
nucleospin
rna
kit
macherey
nagel
use
evalu
knockdown
effici
qpcr
analysi
use
lightcycl
sybr
green
master
kit
roch
primer
use
osbp
microscop
analys
perform
use
hela
bgm
rd
cell
grown
subconflu
coverslip
plate
indic
cell
transfect
plasmid
pegfposbp
pegfpgolgi
encod
gfpfuse
galt
clontech
use
fugen
roch
accord
manufactur
instruct
overnight
express
cell
treat
compound
indic
experi
cell
infect
case
treat
compound
indic
cell
fix
indic
time
point
addit
drug
infect
paraformaldehyd
permeabil
triton
stain
bsa
experi
immunostain
antibodi
case
dna
counterstain
dapi
embed
mowiol
polysci
fluorsav
merck
filipin
stain
cell
fix
permeabil
saponin
stain
filipin
iii
freshli
dilut
mgml
stock
dmso
sigma
pb
embed
fluorsav
cell
imag
use
standard
leica
dmr
olympu
microscop
leica
speii
confoc
laser
scan
microscop
nikon
ti
eclips
microscop
equip
endor
emccdcamera
analyz
coloc
osbp
imag
process
use
imagej
follow
background
signal
deriv
area
without
cell
subtract
imag
singl
cell
outlin
mask
creat
signal
outsid
mask
crop
exclud
calcul
mander
coloc
coeffici
calcul
use
jacop
plugin
bolt
cordelier
manual
set
threshold
quantifi
intens
stain
ro
imag
first
deconvolut
use
ni
advanc
research
softwar
nikon
use
iter
imagej
use
process
infect
cell
select
channel
threshold
fix
valu
intens
stain
structur
quantifi
least
ten
cell
per
condit
calcul
coloc
filipin
imag
first
deconvolut
use
ni
advanc
research
softwar
nikon
iter
imagej
use
select
infect
cell
pearson
coeffici
coloc
least
cell
per
condit
calcul
use
coloc
plugin
default
set
livecel
imag
experi
hela
cell
seed
compartment
cellview
petridish
greiner
bioon
transfect
pegfphosbp
dish
transfer
humidifi
co
temperaturecontrol
chamber
tokaihit
imag
nikon
confoc
laser
scan
microscop
mount
nikon
eclipseti
base
cell
select
imag
refer
imag
taken
longterm
imag
experi
compound
ad
twofold
concentr
dilut
compart
cell
four
differ
posit
per
well
imag
min
addit
drug
imag
taken
fast
possibl
ie
min
interv
interv
gradual
increas
min
interv
hr
addit
compound
onward
prevent
bleach
phototox
imag
min
interv
min
hr
interv
min
final
interv
min
rest
experi
imag
process
quantifi
use
nikon
nisel
softwar
quantif
region
interest
defin
perinuclear
region
stronger
osbp
signal
observ
rest
cytoplasm
ie
golgi
chang
averag
fluoresc
intens
area
quantifi
movi
assembl
use
adob
premier
pro
softwar
vitro
dhe
transport
assay
previous
describ
liposom
assay
use
test
sterol
transfer
activ
osbp
schemat
depict
figur
respect
briefli
sterol
transfer
measur
use
fluoresc
cholesterol
analog
dehydroergosterol
dhe
dhe
transfer
osbp
erlik
liposom
er
like
cover
vapa
golgilik
liposom
golgil
ike
dope
dansylphosphatidylethanolamin
dnspe
upon
dhe
transfer
reson
energi
transfer
fret
dhe
dnspe
due
close
proxim
two
fluorophor
assay
transport
osbp
golgilik
liposom
erlik
acceptor
liposom
detect
use
sensor
consist
phdomain
label
fluorophor
nbd
nbd
ph
sensor
bound
golgilik
liposom
dope
rhodaminep
rhope
nbd
fluoresc
quench
rhodamin
upon
transfer
erlik
liposom
sensor
move
golgilik
erlik
liposom
nbdfluoresc
dequench
egg
pc
liver
pi
brain
ps
brain
dansyl
dn
pe
rhodamin
rhod
pe
lissamin
rhodamin
b
sulfonyl
dogsntani
n
iminodiacet
acid
succinyl
purchas
avanti
polar
lipid
cholesterol
dehydroergosterol
dhe
sigma
aldrich
concentr
dhe
stock
solut
methanol
determin
uvspectroscopi
use
extinct
coeffici
cm
fulllength
osbp
vapa
nbdph
purifi
describ
previous
prepar
liposom
lipid
chloroform
solut
mix
desir
molar
ratio
solvent
remov
rotari
evapor
lipid
film
hydrat
mm
hepe
ph
mm
potassium
acet
hk
buffer
give
suspens
larg
multilamellar
liposom
suspens
frozen
thaw
five
time
extrud
polycarbon
filter
pore
size
use
miniextrud
avanti
polar
lipid
unilamellar
liposom
store
dark
use
within
day
transport
experi
erlik
liposom
contain
egg
pcbrain
molmol
golgilik
liposom
contain
egg
pcliver
pebrain
psliver
pidnsp
molmol
fluoresc
experi
perform
shimadzu
spectrofluorimet
sampl
volum
place
cylindr
quartz
cell
continu
stir
small
magnet
bar
equilibr
dhe
transfer
assay
golgilik
liposom
mol
dnspe
total
lipid
load
incub
vapa
hkm
buffer
hk
buffer
supplement
mm
mgcl
presenc
itz
azol
differ
stock
concentr
dmso
dmsobuff
final
ratio
vv
prior
addit
erlik
liposom
supplement
mol
dhe
total
lipid
osbp
nm
final
concentr
sterol
transport
activ
osbp
monitor
fret
dhe
dnspe
measur
nm
bandwidth
nm
upon
excit
nm
bandwidth
nm
mm
use
determin
maxim
fret
signal
due
full
sterol
equilibr
erlik
golgilik
liposom
transfer
assay
golgilik
liposom
rhodp
total
lipid
incub
hkm
buffer
nm
nbdph
fapp
vapa
presenc
itz
azol
differ
stock
concentr
dmso
transport
follow
measur
nbd
emiss
signal
nm
bandwidth
nm
upon
excit
nm
bandwidth
nm
erlik
liposom
lipid
nm
osbp
sequenti
ad
maxim
signal
correspond
equilibr
type
liposom
determin
mix
control
erand
golgilik
liposom
contain
phffat
osbp
fragment
purifi
describ
flotat
experi
done
previous
detail
bigay
et
al
briefli
phffat
incub
min
room
temperatur
mm
liposom
eror
golgilik
prepar
transfer
assay
without
vapa
andor
itz
indic
suspens
mix
high
sucros
solut
wv
final
sucros
concentr
overlaid
wv
sucros
solut
buffer
without
sucros
sampl
centrifug
rpm
rotor
beckman
hr
bottom
middl
top
fraction
manual
collect
bottom
hamilton
syring
protein
bound
float
liposom
present
top
fraction
analyz
sdspage
purifi
osbp
incub
constant
agit
presenc
trypsin
reaction
stop
min
trypsin
mixtur
addit
mm
pmsf
absenc
residu
fulllength
protein
accumul
ord
fragment
identifi
check
sdspage
dhe
transfer
assay
interact
itz
gfphosbpsii
investig
microscal
thermophoresi
mst
see
eg
jerabekwillemsen
et
al
seidel
et
al
pegfphosbpsii
transfect
cell
use
polyethelyneimin
pei
polysci
medium
replac
express
medium
medium
gibco
supplement
glutamax
gibco
gl
primatonerluf
gl
dglucos
monohydr
gl
nahco
dmso
uml
penicillin
streptomycin
two
day
cell
harvest
centrifug
wash
pb
pellet
cell
pellet
snapfrozen
liquid
nitrogen
store
use
directli
purif
cell
lyse
lysi
buffer
mm
trishcl
mm
nacl
mm
edta
proteas
inhibitor
complex
roch
min
ice
centrifug
min
bound
streptactin
bead
iba
bead
load
column
biorad
unbound
materi
drain
bead
wash
wash
buffer
trishcl
mm
nacl
mm
edta
protein
elut
elut
buffer
wash
buffer
glycerol
biotin
proteas
inhibitor
complex
aliquot
snapfrozen
liquid
nitrogen
store
puriti
protein
prepar
check
sdspage
stain
gelcod
blue
pierc
protein
concentr
determin
use
bradford
reagent
biorad
mst
measur
protein
thaw
ice
centrifug
min
full
speed
tabl
top
centrifug
remov
protein
aggreg
dilut
mst
buffer
mm
trishcl
mm
nacl
mm
mgcl
supplement
itz
serial
dilut
twofold
dilut
step
mst
buffer
protein
itz
dilut
mix
load
standard
treat
capillari
nanotemp
technolog
measur
use
nanotemp
monolith
instrument
nanotemp
technolog
equip
blue
filter
set
compat
gfp
fluoresc
measur
perform
mst
power
led
power
individu
experi
analyz
use
ntanalysi
softwar
nanotemp
technolog
normal
fluoresc
valu
individu
experi
fnorm
export
excel
baselin
correct
substract
averag
first
three
valu
lowest
itz
concentr
plateau
osbp
itz
bound
normal
maxim
bind
use
amplitud
calcul
measur
ntanalysi
softwar
data
three
individu
experi
averag
data
plot
curv
fit
fit
function
law
mass
action
investig
whether
itz
affect
viral
polyprotein
synthesi
process
analyz
viral
protein
h
pi
product
host
protein
sever
suppress
virusinduc
shutoff
capdepend
translat
specif
bgm
cell
infect
moi
hr
pi
cell
starv
methionin
min
subsequ
incub
methionin
presenc
dmso
itz
anoth
min
protein
analyz
sdspage
level
viral
protein
similar
absenc
presenc
itz
indic
viral
polyprotein
synthesi
process
unaffect
itz
figur
renilla
luciferas
level
measur
hr
acut
toxic
drug
treatment
analyz
parallel
use
mt
assay
figur
c
toxic
treatment
ketoconazol
prevent
draw
conclus
antivir
effect
drug
concentr
hela
cell
infect
rlucemcv
treat
hedgehog
pathway
antagonist
figur
renilla
luciferas
level
measur
hr
e
hela
cell
treat
antifung
azol
hr
fix
cholesterol
stain
filipin
cholesterol
redistribut
itz
posaconazol
ketoconazol
fluconazol
voriconazol
f
hela
cell
infect
rlucemcv
treat
figur
renilla
luciferas
level
measur
hr
scale
bar
correspond
asterisk
indic
statist
signific
compar
dmso
control
dmso
gu
guanidin
hcl
known
replic
inhibitor
posa
posaconazol
keto
ketoconazol
flu
fluconazol
vori
voriconazol
hela
cell
stabli
express
treat
dmso
inhibitor
itz
hr
fix
process
microscopi
b
hela
cell
treat
b
fix
stain
antibodi
c
itz
inhibit
accumul
infect
cell
hela
cell
infect
moi
immedi
infect
treat
dmso
itz
fulli
inhibit
replic
hr
pi
cell
fix
stain
antibodi
scale
bar
correspond
hela
cell
transfect
sirna
osbp
scrambl
sirna
neg
control
figur
hr
cell
fix
immunostain
osbp
golgi
marker
nuclei
counterstain
dapi
knockdown
osbp
protein
level
evid
weaker
osbp
stain
golgi
structur
throughout
cytoplasm
note
osbp
knockdown
caus
golgi
becom
less
compact
time
demonstr
knockdown
effici
enough
induc
physiolog
effect
scale
bar
correspond
huh
cell
carri
hcv
genotyp
subgenom
replicon
treat
itz
antifung
azol
replic
determin
day
qpcr
valu
plot
untreat
control
utc
experi
perform
triplic
mean
sem
plot
valu
mean
sd
experi
perform
triplic
compound
cytotox
concentr
data
shown
